HC Wainwright & Co. Reiterates Neutral on Summit Therapeuticsto Neutral
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsReiteration
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) from Neutral to Neutral.
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) from Neutral to Neutral.